| Ytd | -67.07% | |
| 1y | -30.76% |
| Open | 0.51 | Prev Close | 0.50 | Low | 0.48 | High | 0.53 | Mkt Cap | 44.47M |
| Vol | 2.41M | Avg Vol | 2.43M | EPS | -0.48 | P/E | -1.01 | Forward P/E | -3.38 |
| Beta | 2.25 | Short Ratio | 2.79 | Inst. Own | 76.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 1.12 | 200-d Avg | 1.73 | 1yr Est | 7.70 |
CNTX News
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected begi
PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLD
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian canc
PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up,
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC
Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) has been given a consensus recommendation
Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a inte
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Compan
Context Therapeutics (NASDAQ: CNTX) CEO Martin Lehr outlined the company's strategy and upcoming cli
Shares of Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) have been assigned an average r
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
Context Therapeutics (NASDAQ: CNTX - Get Free Report) and Carisma Therapeutics (NASDAQ: CARM - Get F
Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Rep
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
On Thursday, 930 stocks hit new 52-week lows.